PI3K—mTOR信号通路抑制剂抗肿瘤研究新进展(6)
[28] Okabe S， Tauchi T， Tanaka Y，et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation [J]. Asian Pac J Cancer Prev，2013，15(2)：179-189.
[29] Myers AP. New strategies in endometrial cancer： targeting the PI3K/mTOR pathway—the devil is in the details [J]. Clin Cancer Res ......
您现在查看是摘要页，全文长 2374 字符。
[29] Myers AP. New strategies in endometrial cancer： targeting the PI3K/mTOR pathway—the devil is in the details [J]. Clin Cancer Res ......
您现在查看是摘要页，全文长 2374 字符。